DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...

In this article, I employ AI to rank 19 repurposed drugs and supplements by effectiveness against metastatic cancer. To add ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

Revlimid (lenalidomide) can cause side effects that range from mild to serious. More common side effects include nausea, fatigue, and anemia. If side effects from Revlimid become difficult to ...

Image source: Kaboompics.com from Pexels Revlimid (Lenalidomide) is an immunomodulatory medicine that can change the immune system to work more effectively and is a first line medication used to ...

Monjuvi received its first accelerated FDA approval in 2020 for R/R DLBCL in combination with Revlimid. Credit: evan_huang via Shutterstock. FL is the most common indolent form of B-cell non-Hodgkin’s ...